Navigation Links
PharmAthene Reports First Quarter 2011 Financial and Operating Results
Date:5/11/2011

ed; 46,322,026 and 46,238,244 shares issued and outstanding at March 31, 2011 and December 31, 2010, respectively4,6324,624Additional paid-in-capital201,570,845200,847,468Accumulated other comprehensive income1,227,4341,250,497Accumulated deficit(191,967,541)(189,891,884)Total stockholders'  equity10,835,37012,210,705Total liabilities and stockholders' equity

$

23,875,074$

27,199,045PHARMATHENE, INC.UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONSThree months ended March 31,20112010Revenue

$

6,337,722$

3,116,553Operating expenses:Research and development5,820,3744,952,393General and administrative4,939,6545,325,422Depreciation and amortization117,629245,258Total operating expenses10,877,65710,523,073Loss from operations(4,539,935)(7,406,520)Other income (expense):Interest income3,1543,483Interest expense(15,435)(948,150)Other income (expense)(11,906)139,422Change in market value of derivative instruments2,488,465267,496Total other income (expense)2,464,278(537,749)Net loss

$

(2,075,657)$

(7,944,269)Basic and diluted net loss per share

$

(0.04)$

(0.28)Weighted average shares used in calculation of basic and diluted net loss per share46,276,87428,172,802
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. PharmAthene to Host Year-End 2010 Earnings Conference Call and Webcast on Monday, March 28, 2011
2. PharmAthene Strengthens Scientific Leadership and Program Management for Future Growth
3. PharmAthene Receives FDA Clearance to Reinitiate Clinical Testing of Valortim®
4. PharmAthene Reports Third Quarter 2010 Financial and Operational Results
5. PharmAthene Receives Four Therapeutic Discovery Project Grants Totaling Approximately $850,000
6. PharmAthene Announces Pricing of $15 Million Public Offering
7. PharmAthene Announces Proposed Common Stock Offering
8. PharmAthene Announces $3.9 Million Registered Direct Offering
9. PharmAthene CEO To Participate on Biosecurity Panel at the 2010 BIO International Conference
10. PharmAthene Appoints Mitchel Sayare, Ph.D. to the Companys Board of Directors
11. PharmAthene Reports Year-End 2009 Financial and Operational Results and Provides Update On Ongoing Litigation With SIGA Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... Diego, CA (PRWEB) April 24, 2015 ... Diego and other San Diego area universities, including UCSD ... 28 to judges from prominent local, national and nonprofit ... funding in the 5th Annual Social Innovation Challenge ... have proposed unique social venture ideas addressing a diverse ...
(Date:4/24/2015)... /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ) has ... of bio-succinic acid used to produce a new ... that Bayer MaterialScience has begun commercializing.    ... eco, a series of bio-based waterborne polyurethane dispersions ... 65%.  IMPRANIL ® eco has been developed ...
(Date:4/24/2015)... 2015 PAREXEL International Corporation (NASDAQ: ... announced that Partnerships in Clinical Trials named PAREXEL,s ... Clinical Innovator of the Year.  The honor recognizes Mr. ... Company,s Perceptive MyTrials ® Data-Driven Monitoring solution. ... the 2015 Partnership Awards in Boston ...
(Date:4/23/2015)... 2015 The Thomas Brain Health ... a groundbreaking pilot study to see if early ... as little as three to six months. , ... nutritional medicine—will aggressively target and simultaneously treat the ... aging brain. These include oxidative stress, neuroinflammation, mitochondrial ...
Breaking Biology Technology:5th Annual Social Innovation Challenge at University of San Diego - Students Pitch to Live Judging Panel to Take Home $75K 25th Annual Social Innovation Challenge at University of San Diego - Students Pitch to Live Judging Panel to Take Home $75K 3Bayer MaterialScience Names BioAmber As Its Supplier For New Product Line - Bio-succinic acid forms backbone of innovative new bio-based polyurethanes for textiles 2Bayer MaterialScience Names BioAmber As Its Supplier For New Product Line - Bio-succinic acid forms backbone of innovative new bio-based polyurethanes for textiles 3Bayer MaterialScience Names BioAmber As Its Supplier For New Product Line - Bio-succinic acid forms backbone of innovative new bio-based polyurethanes for textiles 4PAREXEL Honored With 2015 Clinical Innovator Of The Year Award From Partnerships In Clinical Trials 2PAREXEL Honored With 2015 Clinical Innovator Of The Year Award From Partnerships In Clinical Trials 3PAREXEL Honored With 2015 Clinical Innovator Of The Year Award From Partnerships In Clinical Trials 4PAREXEL Honored With 2015 Clinical Innovator Of The Year Award From Partnerships In Clinical Trials 5New Study Looks to Reverse Alzheimer’s Disease 2New Study Looks to Reverse Alzheimer’s Disease 3
... , , , Multiporator , , , , , , ... Transfection Protocol , Protocol No. 4308 915.046 11/2001 , , ... , , Cell line , ... Transfection with , pActin-SV-EGFP, ...
... , , , , , Multiporator , , , ... Transfection Protocol , Protocol No. 4308 915.020 11/1999 ... , , , , , , ... line), , , ...
... , , Multiporator / Electroporator 2510 , , , , , , ... Transformation Protocol , Protocol No. 4308 915.516 12/2001 , , ... , , , Microorganism , ... Cell type , Yeast, ...
Cached Biology Technology:L2 2Jurkat 2Jurkat 3Kluyveromyces lactis 2
(Date:4/9/2015)... , April 9, 2015 Synaptics Inc. (NASDAQ: ... solutions, announced today that it will report financial results ... April 23, 2015, after the close of market. The ... and investors at 2:00 p.m. PT (5:00 p.m. ET), ... To participate on the live call, analysts and ...
(Date:4/2/2015)... , April 2, 2015 ... Q1 2015 attributed to somewhat higher than 125 MSEK. ... the year-end report 2014 that revenues for Q1 2015 ... the company reported for Q4 2014. The operating result ... be negative. The complete interim report will as previously ...
(Date:3/31/2015)... 2015   Guidepoint , a leading global research ... Pain Management TRACKER, part of the Guidepoint TRACKER ... the medical device and therapeutics markets. The Post-Surgical Pain ... volumes, market share, and adoption rates across three major ... surgery. The Post-Surgical Pain Management TRACKER will ...
Breaking Biology News(10 mins):Synaptics to Report Third Quarter Results on April 23 2Fingerprint Cards Revises Revenues for Q1 2015 2Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3
... brain can harm neural tissue and even alter behavior, a ... shown. But these consequences can be mitigated by a drug ... of dementia associated with cumulative damage to miniscule blood vessels ... the December 16 advance online edition of Nature Neuroscience ...
... PHILADELPHIA Research from the Perelman School of Medicine at ... that sons of male rats exposed to cocaine are resistant ... changes in physiology are passed down from father to son. ... Nature Neuroscience . "We know that genetic factors ...
... at the International Osteoporosis Foundation,s Asia-Pacific Osteoporosis Meeting, researchers ... a new research study that showed the benefits of ... loss in postmenopausal women. Researchers carried out a ... involving a total of 140 women. The women, aged ...
Cached Biology News:Even the smallest stroke can damage brain tissue and impair cognitive function 2Penn Study shows resistance to cocaine addiction may be passed down from father to son 2Community-based nutrition education shown to be successful in increasing calcium intake 2
... The Zero Blunt TOPO ... Sequencing is designed for ... of blunt-end PCR products. ... 5-minute TOPO Cloning and ...
...
nucleophosmin (nucleolar phosphoprotein B23, numatrin), mRNA...
Acrylamide PAGE 40% Solution, 1 l. Category: Electrophoresis Systems & Standards & Reagents, Electrophoresis Standards and Reagents, Gel Casting Chemicals....
Biology Products: